Biotech - Spark Newswire

1 minute read

Junshi Biosciences And Coherus Biosciences Announced Results Of A Final Analysis Of Overall Survival From Jupiter-02 Phase 3 Trial Of Toripalimab Plus Gemcitabine Plus Cisplatin As The First-line Treatment Recurrent Or Metastatic Nasopharyngeal Carcino…

February 15, 9:32 AM

This final analysis demonstrated a statistically significant and clinically meaningful improvement in overall survival in nasopharyngeal carcinoma patients treated with toripalimab plus chemotherapy compared to

CHRS

1 minute read

Akari Therapeutics Announced Updates On Progress In The Pre-clinical Development Program For Long-Acting PAS-Nomacopan As A Potential Treatment For Geographic Atrophy Secondary To Dry Age-related Macular Degeneration

By Benzinga Newsdesk

February 15, 9:22 AM

Akari is targeting an Investigational New Drug application submission to the FDA in the first half of 2024. Composition of matter patent application filed on long-acting PAS-nomacopan versions, which, if granted,

AKTX

1 minute read

Taiwan-Based Formosa Pharmaceuticals Has Entered Into A Collaboration Agreement With Eyenovia For The Development Of Ophthalmic Therapeutics. Deal Terms Not Disclosed

By Benzinga Newsdesk

February 15, 4:31 AM

The collaboration will combine Formosa's proprietary APNT nanoparticle formulation platform with Eyenovia's Optejet dispensing technology for the development of new ophthalmic therapies

EYEN

4 minute read

Collaboration With Kiora Pharmaceuticals And The Royal Adelaide Hospital, Leading Australian CRO, Accelagen Clinical Trial Underway To Improve Vision In Individuals With Advanced Retinitis Pigmentosa

By Happy Mohamed

February 14, 5:22 PM

Putting Australian clinical research on the map globally, comes the ground-breaking first-in-human clinical trial for KIO-301. MELBOURNE, Australia, Feb. 14, 2023 /PRNewswire/ -- In collaboration with US-based

KPRX

1 minute read

Humanigen Has Received A Notice Of Allowance For Its U.S. Patent Application 16/652,977 Titled “Methods Of Treating Immunotherapy-Related Toxicity Using A GM-CSF Antagonist”.

By Happy Mohamed

February 14, 4:59 PM

https://patentcenter.uspto.gov/#!/applications/16652977/ifw/docs

HGEN

1 minute read

Cameroon Regional Health Official: Two Suspected Marburg Virus Cases Detected In Olamze Commune, Near Eq. Guinea Border On Monday

By Happy Mohamed

February 14, 2:18 PM

- Reuters

SRPT

1 minute read

US Judge Intends To Dismiss Johnson & Johnson’s Talc Subsidiary Bankruptcy

By Vandana Singh

February 14, 1:41 PM

A three-judge panel of the Philadelphia-based 3rd U.S. Circuit Court of Appeals ruled to dismiss Johnson & Johnson's (NYSE: JNJ) subsidiary's bankruptcy case regarding talc-related claims.

JNJ

1 minute read

Astrazeneca’s Bi-specific Antibody, Rilvegostomig, Derived From Compugen’s Com902, Is Expected To Progress Into Phase 3 This Year

By Benzinga Newsdesk

February 14, 10:57 AM

AstraZeneca announced plans to initiate a Phase 3 trial for rilvegostomig (previously AZD2936), a PD-1/TIGIT bi-specific antibody, and is also developing an expanded Phase 2 program. COM902, Compugen's

AZN

2 minute read

Novel Approach To Treating Advanced Liver Cancer With Namodenoson Published In Leading Scientific Journal: 12-Month Survival Of 44% For Namodenoson Vs. 18% For Placebo

By Happy Mohamed

February 14, 9:16 AM

Namodenoson is being evaluated in a pivotal Phase III study Namodenoson is approved for compassionate use in the treatment of liver cancer in Israel and Romania Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI), a

CANF

1 minute read

Fusion Pharma Raises $60M To Fund Acquisition Of Prostate Cancer-Targeted Radiopharmaceutical

By Vandana Singh

February 14, 8:59 AM

Fusion Pharmaceuticals Inc (NASDAQ:FUSN) acquired the investigational new drug application for an ongoing Phase 2 TATCIST trial evaluating 225Ac-PSMA…

FUSN